Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 73–96 of 157
BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.
Intraoperative MRI technology enables surgeons to image the brain during active neurosurgery, reducing procedure time by one to two hours and allowing real-time adjustments based on functional data rather than preoperative imaging. This capability addresses a fundamental constraint in neurosurgical care: the gap between what the surgeon sees at the start of an operation and the patient's actual physiological state during intervention.
Cortechs.ai and Siemens Healthineers have partnered to integrate NeuroQuant, an FDA-cleared AI neuroimaging tool, into clinical workflows for automated brain lesion tracking and volumetric quantification. This expands clinician access to objective, longitudinal brain imaging data for monitoring neurological disease progression and treatment response, including anti-amyloid therapies for Alzheimer's disease.
Sequential, a Cambridge-based skin health testing company, raised $3.5 million to build an AI discovery engine powered by over 50,000 clinical samples and 4,000+ ingredients. The platform measures microbial and host biomarkers to identify which ingredients actually affect skin function—moving personal care from marketing claims to measurable biological outcomes.
Plasma biomarkers (phosphorylated tau, amyloid-beta, and neurofilament light) accurately distinguish Alzheimer's disease from frontotemporal lobar degeneration across Latin American populations when integrated with neuroimaging and machine learning algorithms. This addresses a critical gap in early detection capability for underrepresented populations.
Cardiovascular magnetic resonance imaging in adults over 75 reveals frequent incidental findings, demonstrating that large-scale aging cohorts require structured protocols for identifying, communicating, and managing unexpected discoveries. This work establishes a baseline for governance frameworks in gerontological research.
Annovis is combining continuous movement monitoring via FDA-cleared AI with skin-based alpha-synuclein biomarkers to measure treatment response in a 36-month Parkinson's trial. This dual approach—capturing real-time motor dysfunction alongside objective pathological markers—establishes measurable endpoints for evaluating buntanetap's disease-modifying potential.
The global life sciences analytics market is projected to double from $11.1 billion in 2024 to $23.17 billion by 2033, driven by AI-enabled drug discovery, clinical trial optimization, and precision medicine workflows. This infrastructure expansion directly influences how treatments are identified, validated, and personalized to individual patients.
Eli Lilly's $2.75 billion collaboration with Insilico Medicine represents a shift from software licensing to pipeline asset acquisition, validating AI-driven drug discovery as a viable approach to therapeutic development. This partnership signals pharmaceutical industry confidence in computational approaches to identifying and developing novel compounds, with potential applications across multiple disease areas including aging-related conditions.
Researchers used AI to redesign antibody fragments that can function inside human cells, targeting misfolded proteins linked to Alzheimer's, Parkinson's, Huntington's, and motor neurone disease. This intracellular delivery approach addresses a fundamental limitation of conventional antibodies, which cannot access disease-driving proteins within neurons.
PET and MRI imaging can now differentiate LATE (limbic-predominant age-related TDP-43 encephalopathy) from Alzheimer's disease in living patients, addressing a diagnostic gap that has resulted in widespread misclassification. Since LATE arises from different pathology (TDP-43 protein clumping) than Alzheimer's (amyloid and tau accumulation), accurate differentiation is essential for appropriate treatment selection and prognosis.
Biological age, calculated from a 10-marker panel, correlates with HDL cholesterol, vitamin D, and immune function (CD4+ ratio) independently of chronological age. Subjects with lower biological age scores showed favorable values in these markers, suggesting they function as drivers of the aging process rather than mere correlates.
Epigenetic aging—the divergence between chronological age and biological age—emerges as a measurable marker influenced by both genetic predisposition and modifiable molecular factors. Understanding these mechanisms provides actionable insight into why some individuals age more slowly at the cellular level and how interventions targeting epigenetic signatures may extend healthspan.
Imaging-derived biological age—a measure of structural aging across multiple organs—independently predicts mortality and age-related disease risk beyond chronological age. This multi-organ assessment reveals that heterogeneous aging patterns across tissues provide clinically actionable information for longevity planning and intervention timing.
Physical fitness metrics correlate with DNA methylation patterns of circulating proteins, revealing molecular pathways that link muscular strength, aerobic capacity, body composition, and cognitive function to reduced risk of age-related diseases. This molecular mapping enables patient-level disease risk stratification based on combined fitness and epigenetic measurements.
Proteomic analysis identified 311 plasma proteins whose expression patterns correlate with both chronological age and disease burden in older adults, representing candidate biomarkers of biological aging. These proteins suggest shared regulatory pathways between aging and chronic disease progression and may enable risk stratification and intervention monitoring.
A Cell Genomics study demonstrates that age-related systemic inflammation (inflammaging) correlates with epigenetic aging as measured by established epigenetic clocks. This connection bridges two major aging hallmarks and suggests chronic low-grade immune activation reflects measurable changes in gene expression patterns independent of overt disease.
A pilot randomized controlled trial investigates whether reducing glycation stress—the accumulation of sugar-derived damage to proteins—can slow aging markers in postmenopausal women. Glycation is a hallmark of aging that accelerates decline across multiple physiological systems, making this intervention relevant to the practical toolkit of longevity medicine.
Death Clock has launched Life Lab, an AI-driven health concierge that integrates blood biomarker analysis with personalized preventive guidance to help users close the gap between their current and optimized projected lifespan. The service aggregates laboratory testing, medical records, and wearable data to identify actionable interventions across four major chronic disease categories.
20/20 BioLabs launched OneTest for Longevity, a blood test combining inflammatory biomarkers, lifestyle data, and AI to identify chronic disease risk before clinical symptoms emerge. The platform translates biomarker patterns into actionable dietary and lifestyle modifications, addressing inflammation and stress response as primary drivers of aging and age-related disease.
Aging retinas undergo extensive epigenetic reprogramming affecting approximately 40% of rhythmically expressed genes, driven primarily by decreased histone H3K4 methylation rather than changes to core circadian clock factors. These chromatin-level shifts disrupt the diurnal transcriptional rhythms critical for retinal function and systemic circadian synchronization.
TMRW, an Australian longevity platform, secured $7 million in seed funding to expand clinical services and deepen biological age assessment through epigenetic testing in partnership with TruDiagnostic. The company differentiates itself by analyzing approximately 1,700 biological data points and integrating clinical support alongside diagnostics, moving beyond dashboard-only models.
A $6.2 million NIH grant funds AI-driven analysis of 1,800 Alzheimer's-linked genes to identify genetic targets upstream of amyloid pathology, shifting focus from symptomatic treatment to early-stage vulnerability. Current amyloid-targeting drugs slow progression at best; identifying genetic determinants of susceptibility may enable earlier, more precise intervention before neurodegeneration becomes symptomatic.
Sky Labs received UK regulatory approval for CART PLATFORM, a cuffless ring-based blood pressure monitor that integrates wearable hardware, mobile app, and cloud analytics. The authorization enables prescription distribution through UK pharmacies and hospitals, establishing clinical-grade continuous blood pressure monitoring as an accessible diagnostic tool.
